Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2024 13:00 ET | Source: DelveInsight Business Research LLP

Excessive Daytime Sleepiness Market is Projected to Boost at a Moderate Growth Rate by 2032, Predicts DelveInsight | Key Companies in the Market - Avadel Pharmaceutical, Axsome Therapeutic, Theranexus, XWPharma, Takeda Pharmaceutical

New York, USA, April 09, 2024 (GLOBE NEWSWIRE) -- Excessive Daytime Sleepiness Market is Projected to Boost at a Moderate Growth Rate by 2032, Predicts DelveInsight | Key Companies in the Market -...
August 05, 2020 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy

Designation offers potential for expedited development and review FDA Orphan Drug Designation previously granted to Axsome for AXS-12 in narcolepsy Third FDA Breakthrough Therapy designation...
December 03, 2019 06:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy

Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p<0.001 on primary endpoint) Reduced excessive daytime sleepiness compared to placebo (p=0.003 on ESS;...